Everolimus Zentiva 2

DRUG2 trials

Sponsors

Genentech Inc., Arvinas Estrogen Receptor Inc.

Conditions

ER+Estrogen Receptor (ER)-PositiveHER2-NegativeHER2– Advanced or Metastatic Breast CancerLocally Advanced or Metastatic Breast Cancer previously treated with a CDK4/6 inhibitor and endocrine therapy

Phase 1

A Phase 1b Trial of ARV-471 in Combination with Everolimus in Patients with ER+, HER2– Advanced or Metastatic Breast Cancer

CompletedCTIS2024-513284-30-00

Arvinas Estrogen Receptor Inc.ER+, HER2– Advanced or Metastatic Breast Cancer

Start: 2023-03-22End: 2025-08-25Target: 1Updated: 2025-02-13

Phase 3

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared with the Physician’s Choice of Endocrine Therapy Plus Everolimus in Patients with Estrogen Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer

Active, not recruitingCTIS2023-506821-12-00

Genentech Inc.Estrogen Receptor (ER)-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer previously treated with a CDK4/6 inhibitor and endocrine therapy

Start: 2023-10-12Target: 59Updated: 2025-12-17